Bosanjin Supporting Global Expansion of Pharma and Bio... Offering Partnering Opportunities with Big Pharma

The Korea Health Industry Development Institute announced on the 20th that it held the 'Global Partnership Seminar & Partnering' from the 15th to the 17th to promote open innovation in the pharmaceutical and bio industries.

[Photo by Korea Health Industry Development Institute]

This event was organized as part of the 'Pharmaceutical Bio Open Innovation Week 2023,' jointly hosted by the Korea Health Industry Development Institute, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, and the Korea Institute of Toxicology. Representatives in charge of business development from the headquarters of 13 global pharmaceutical companies, including Bristol-Myers Squibb (BMS), MSD (Merck & Co., USA), Novo Nordisk, Roche, Merck, Sanofi, Amgen, Eisai, and Johnson & Johnson (J&J), attended to present collaboration strategies with Korea and seek partnerships through one-on-one meetings with domestic companies.

In particular, at the Global Partnership Seminar & Partnering held on the 15th, 11 global pharmaceutical companies such as Amgen, J&J, MSD, Novo Nordisk, BMS, and Roche presented their key areas of interest, collaboration strategies, and successful cases of open innovation cooperation. A total of 216 industry stakeholders from the pharmaceutical and bio sectors attended the seminar on-site, demonstrating strong enthusiasm for global collaboration. Following this, on the 16th and 17th, the 13 pharmaceutical companies held in-depth one-on-one meetings with domestic pharmaceutical firms to explore collaboration opportunities.

The one-on-one partnering sessions were conducted with companies pre-selected by global pharmaceutical companies after reviewing application documents submitted in advance. Out of a total of 161 applicant companies, 87 secured the opportunity to engage in direct discussions with global pharmaceutical companies. Over the two days, a total of 126 partnering sessions were held both online and offline with 13 global pharmaceutical companies.

Kim Yong-woo, Head of the Pharmaceutical Bio Industry Division at the Development Institute, said, “Through these exchange opportunities, we hope global pharmaceutical companies gain confidence in domestic technologies and domestic companies achieve tangible results in global collaboration, creating a good opportunity for mutual growth.” He added, “As this is the third year the global open innovation event has been held and it is gradually establishing itself, we will continue to provide such opportunities in the future.”

This content was produced with the assistance of AI translation services.